We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LGEN:LSELegal & General Group Plc Analysis

Data as of 2026-06-14 - not real-time

£280.70

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

LGEN is trading at 280.7p, comfortably above its 20‑day (≈270p), 50‑day (≈262p) and 200‑day (≈253p) simple moving averages, indicating strong bullish momentum. The 14‑day RSI sits at 68, suggesting optimism but still below typical over‑bought thresholds. MACD shows a bullish crossover with the line (4.42) above the signal (3.79) and a positive histogram, reinforcing the upward bias. Price remains above the identified support at 258.2p and well under the 300p resistance, giving a healthy cushion. Volume trends are weakening, and 30‑day volatility is elevated at ~26%, implying price swings may intensify. The Fear & Greed Index reads “Extreme Greed” (89.9), reflecting strong market appetite for risk‑on assets like LGEN.
Fundamentally, revenue grew 14% YoY, yet margins are modest (gross 25%, operating 7%) and free cash flow is negative, raising concerns about cash generation. The dividend yield of 7.8% looks attractive, but a payout ratio above 260% is unsustainable. Valuation metrics are stretched: P/E of 35 versus an industry average of 17, and a price‑to‑book of 8.8, while the DCF model implies a fair value only modestly below current price, yielding a –6% upside/downside. Analyst consensus is neutral (hold) and Jefferies recently cut the rating to underperform with a 185p target, citing earnings pressure. Recent strategic moves, including £1.5bn of non‑core disposals and the £1.8bn sale of its U.S. protection business, aim to simplify the balance sheet and fund future growth. Combined, these factors suggest the stock is overvalued in the near term despite a supportive technical backdrop.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Recent Jefferies downgrade and sub‑200p target
  • Overvalued multiples relative to peers
  • High dividend payout ratio unsustainable

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Ongoing asset disposals improving balance sheet
  • Bullish technical positioning above key SMAs
  • Potential for earnings stabilization after US protection sale

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Diversified insurance and asset‑management franchise
  • Attractive dividend yield if payout ratio can be normalized
  • Low beta indicating defensive characteristics in volatile markets

Key Metrics & Analysis

Financial Health

Revenue Growth13.90%
Profit Margin5.39%
P/E Ratio35.1
ROE17.86%
ROA0.11%
Debt/Equity2477.34
P/B Ratio8.8
Op. Cash Flow£4.5B
Free Cash Flow£-17395374080
Industry P/E16.8

Technical Analysis

TrendBullish
RSI67.8
Support£258.20
Resistance£300.00
MA 20£269.99
MA 50£261.98
MA 200£252.67
MACDBullish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

Fair Value£9,971.51
Target Price£263.76
Upside/Downside-6.04%
GradeOvervalued
TypeBlend
Dividend Yield7.76%

Risk Assessment

Beta0.43
Volatility25.91%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.